y异种移植肿瘤模型（CDX Model）
异种移植肿瘤模型（Cell line-Derived Xenograft ，CDX)是指将人源的细胞系经过体外培养后，通过皮下、静脉或者原位的方式接种到免疫缺陷的小鼠体内的一种异种移植模型。该动物模型常用于药效学评价，是目前抗肿瘤药物临床前药效学评价最常用的体内模型之一，该模型具有实验周期短、建模成功率高的特点，是目前应用最广泛的肿瘤模型，可用于抗肿瘤药物的体内筛选、药效学评价、PK/PD分析、联合给药方案测试等。
CDX models案例
（1）Human gastric cancer——SNU16
|
TAS120 5mpk |
Days after treatment |
|||||||
|
0 |
3 |
7 |
10 |
14 |
17 |
21 |
24 |
|
|
T/C (%) |
- |
25.74 |
-6.96 |
-10.13 |
-9.63 |
-7.05 |
-5.25 |
-3.54 |
|
TGI (%) |
- |
74.26 |
106.96 |
110.13 |
109.63 |
107.05 |
105.25 |
103.54 |
|
P value |
0.9975 |
0.0002 |
0.0002 |
0.0001 |
0.0000 |
0.0000 |
0.0000 |
0.0000 |
（2）Human Pancreatic ductal adenocarcinoma cancer——MIA PACA-2
|
AMG510 10mpk |
Days after treatment |
||||||||||||
|
0 |
3 |
6 |
9 |
13 |
16 |
20 |
23 |
27 |
30 |
34 |
37 |
41 |
|
|
T/C(%) |
/ |
-72.8 |
-71.0 |
-84.9 |
-75.5 |
-45.4 |
-26.5 |
-16.9 |
-11.1 |
-9.9 |
-8.4 |
-6.5 |
-4.6 |
|
TGI(%) |
/ |
172.8 |
171.0 |
184.9 |
175.5 |
145.4 |
126.5 |
116.9 |
111.1 |
109.9 |
108.4 |
106.5 |
104.6 |
|
P Value |
0.9646 |
0.0011 |
0.0002 |
0.0000 |
0.0000 |
0.0000 |
0.0000 |
0.0000 |
0.0000 |
0.0000 |
0.0000 |
0.0000 |
0.0000 |
（3）Human esophageal squamous cell carcinoma cancer——KYSE 520
|
shp099 and RMC4550 |
Days after treatment |
||||||||||||
|
D0 |
D4 |
D7 |
D11 |
D14 |
D18 |
D21 |
D25 |
D28 |
D32 |
D35 |
D39 |
||
|
T/C(%) |
shp099 50mpk |
- |
-42.2 |
-24.3 |
-2.4 |
7.5 |
13.8 |
10.1 |
11.7 |
11.3 |
9.1 |
8.5 |
7.7 |
|
RMC4550 10mpk |
- |
10.1 |
-10.1 |
10.3 |
15.0 |
20.1 |
20.0 |
20.7 |
20.5 |
17.8 |
18.2 |
15.3 |
|
|
TGI(%) |
shp099 50mpk |
- |
142.2 |
124.3 |
102.4 |
92.5 |
86.2 |
89.9 |
88.3 |
88.7 |
90.9 |
91.5 |
92.3 |
|
RMC4550 10mpk |
- |
89.9 |
110.1 |
89.7 |
85.0 |
79.9 |
80.0 |
79.3 |
79.5 |
82.2 |
81.8 |
84.7 |
|
|
P value |
shp099 50mpk |
0.9533 |
0.0015 |
0.0000 |
0.0000 |
0.0005 |
0.0001 |
0.0002 |
0.0000 |
0.0001 |
0.0000 |
0.0000 |
0.0000 |
|
RMC4550 10mpk |
0.9347 |
0.0177 |
0.0001 |
0.0000 |
0.0009 |
0.0001 |
0.0007 |
0.0001 |
0.0002 |
0.0000 |
0.0001 |
0.0000 |
|
（4）Human non-small cell lung cancer cells——NCI-H358
|
AMG510 10mpk |
Days after treatment |
||||||||||
|
0 |
3 |
7 |
11 |
14 |
18 |
21 |
25 |
28 |
32 |
35 |
|
|
T/C(%) |
/ |
-19.4 |
-12.3 |
-9.8 |
-7.6 |
-4.8 |
-3.3 |
-2.5 |
-3.0 |
-0.1 |
1.4 |
|
TGI(%) |
/ |
119.4 |
112.3 |
109.8 |
107.6 |
104.8 |
103.3 |
102.5 |
103.0 |
100.1 |
98.6 |
|
P Value |
0.9669 |
0.0137 |
0.0427 |
0.0206 |
0.0214 |
0.0380 |
0.0155 |
0.0160 |
0.0012 |
0.0009 |
0.0008 |
（5）Human liver cancer-Hep3B
|
Erdafitinib 20mpk |
Days after treatment |
|||||
|
0 |
3 |
6 |
8 |
10 |
13 |
|
|
T/C (%) |
- |
61.0 |
50.4 |
61.4 |
60.4 |
67.4 |
|
TGI (%) |
- |
39.0 |
49.6 |
38.6 |
39.6 |
32.6 |
|
P value |
0.9636 |
0.1468 |
0.0015 |
0.0019 |
0.0005 |
0.0101 |
（6）Human bladder cancer-RT112/84
|
Erdafitinib 30mpk |
Days after treatment |
|||||
|
D0 |
D4 |
D8 |
D11 |
D15 |
D18 |
|
|
T/C (%) |
- |
43.8 |
2.7 |
-2.0 |
-4.4 |
-3.3 |
|
TGI (%) |
- |
56.2 |
97.3 |
102.0 |
104.4 |
103.3 |
|
P value |
0.7130 |
0.2073 |
0.0039 |
0.0035 |
0.0008 |
0.0003 |
（7）Human b-lymphocyte tumor cells-KARPAS422
|
EED226 100mpk |
Days after treatment |
|||||||
|
0 |
2 |
6 |
9 |
13 |
15 |
17 |
20 |
|
|
T/C(%) |
/ |
91.9 |
86.0 |
86.0 |
63.8 |
56.1 |
30.5 |
17.1 |
|
TGI(%) |
/ |
8.1 |
14.0 |
14.0 |
36.2 |
43.9 |
69.5 |
82.9 |
|
P Value |
0.9894 |
0.7911 |
0.4838 |
0.2936 |
0.0056 |
0.0016 |
0.0000 |
0.0000 |
